These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1234 related items for PubMed ID: 27999193

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Platinum pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via DUB inhibition-dependent caspase activation and Bcr-Abl downregulation.
    Lan X, Zhao C, Chen X, Zhang P, Zang D, Wu J, Chen J, Long H, Yang L, Huang H, Wang X, Shi X, Liu J.
    Cell Death Dis; 2017 Jul 06; 8(7):e2913. PubMed ID: 28682311
    [Abstract] [Full Text] [Related]

  • 5. HS-543 induces apoptosis of Imatinib-resistant chronic myelogenous leukemia with T315I mutation.
    Kim SJ, Jung KH, Yan HH, Son MK, Fang Z, Ryu YL, Lee H, Lim JH, Suh JK, Kim J, Lee S, Hong S, Hong SS.
    Oncotarget; 2015 Jan 30; 6(3):1507-18. PubMed ID: 25483100
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
    Yun SM, Jung KH, Kim SJ, Fang Z, Son MK, Yan HH, Lee H, Kim J, Shin S, Hong S, Hong SS.
    Cancer Lett; 2014 Jun 28; 348(1-2):50-60. PubMed ID: 24657654
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Characterization of imatinib-resistant K562 cell line displaying resistance mechanisms.
    Hekmatshoar Y, Ozkan T, Altinok Gunes B, Bozkurt S, Karadag A, Karabay AZ, Sunguroglu A.
    Cell Mol Biol (Noisy-le-grand); 2018 May 15; 64(6):23-30. PubMed ID: 29808796
    [Abstract] [Full Text] [Related]

  • 10. CD-200 induces apoptosis and inhibits Bcr-Abl signaling in imatinib-resistant chronic myeloid leukemia with T315I mutation.
    Fang Z, Jung KH, Yan HH, Kim SJ, Son MK, Rumman M, Lee H, Kim KW, Yoo HD, Hong SS.
    Int J Oncol; 2015 Jul 15; 47(1):253-61. PubMed ID: 25963192
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells.
    Carter BZ, Mak PY, Mak DH, Ruvolo VR, Schober W, McQueen T, Cortes J, Kantarjian HM, Champlin RE, Konopleva M, Andreeff M.
    Oncotarget; 2015 Oct 13; 6(31):30487-99. PubMed ID: 26431162
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Preclinical development of a novel BCR-ABL T315I inhibitor against chronic myeloid leukemia.
    Gupta P, Zhang GN, Barbuti AM, Zhang X, Karadkhelkar N, Zhou J, Ding K, Pan J, Yoganathan S, Yang DH, Chen ZS.
    Cancer Lett; 2020 Mar 01; 472():132-141. PubMed ID: 31837444
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The chimeric ubiquitin ligase SH2-U-box inhibits the growth of imatinib-sensitive and resistant CML by targeting the native and T315I-mutant BCR-ABL.
    Ru Y, Wang Q, Liu X, Zhang M, Zhong D, Ye M, Li Y, Han H, Yao L, Li X.
    Sci Rep; 2016 Jun 22; 6():28352. PubMed ID: 27329306
    [Abstract] [Full Text] [Related]

  • 18. Blockade of the interaction between Bcr-Abl and PTB1B by small molecule SBF-1 to overcome imatinib-resistance of chronic myeloid leukemia cells.
    Elgehama A, Chen W, Pang J, Mi S, Li J, Guo W, Wang X, Gao J, Yu B, Shen Y, Xu Q.
    Cancer Lett; 2016 Mar 01; 372(1):82-8. PubMed ID: 26721204
    [Abstract] [Full Text] [Related]

  • 19. Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment.
    Oaxaca DM, Yang-Reid SA, Ross JA, Rodriguez G, Staniswalis JG, Kirken RA.
    Tumour Biol; 2016 Sep 01; 37(9):12643-12654. PubMed ID: 27444277
    [Abstract] [Full Text] [Related]

  • 20. Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia.
    Bandyopadhyay S, Li J, Traer E, Tyner JW, Zhou A, Oh ST, Cheng JX.
    PLoS One; 2017 Sep 01; 12(7):e0179558. PubMed ID: 28719608
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 62.